Submitted by thewallstreetjournal7221 in business
Drugmaker is doubling down on cancer and neurology as it seeks to replace falling revenue from its top sellers
Submitted by thewallstreetjournal7221 in business
Drugmaker is doubling down on cancer and neurology as it seeks to replace falling revenue from its top sellers